Blood test from Alliance trial guides use of anti-inflammatory drug to lower colon cancer recurrence risk

Results of a data analysis from an Alliance for Clinical Trials in Oncology randomized phase III trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to treatment after surgery, might help those who still have traces of cancer in their blood. The analysis showed that patients with signs of cancer in their blood measured by Signatera™, a circulating tumor DNA (ctDNA) test, tended to have worse outcomes. However, those who took celecoxib after s

• Read more